Posts by Nanbiosis

NANBIOSIS U26 Contributes to New Study Using CMR and PET to Track Myocardial Infarction Progression in Mice

Multimodal CMR/PET imaging reveals key differences in infarct evolution in mice. NANBIOSIS U26 contributed technical expertise and advanced imaging support.

Valencia, December 2025 — A new scientific publication, “Characterization of Infarct Size and Remodeling Using CMR and PET in Mice Models of Reperfused and Non-Reperfused Myocardial Infarction” (Diagnostics, 2025), highlights the value of combining cardiovascular magnetic resonance (CMR) and positron emission tomography (PET) for non-invasive, longitudinal evaluation of heart damage in preclinical models of myocardial infarction. The study features the participation of NANBIOSIS Unit 26, which contributed both technical expertise and advanced imaging infrastructure.

A multimodal approach to understanding Heart Injury

The research compares two experimental mouse models of myocardial infarction—one with permanent coronary occlusion (non-reperfused) and another with transient occlusion followed by reperfusion. Using CMR and fluorine-18 FDG PET imaging at baseline and at 1, 7, and 21 days after infarction, the authors assessed:

• Infarct size
• Systolic function
• Myocardial glucose metabolism

Masson’s trichrome histology served as the reference standard for infarct size at the chronic phase.

The results showed that both models exhibited infarction, reduced systolic function, and decreased glucose metabolism as early as 24 hours post-event. By day 21, reperfused mice demonstrated smaller infarcts and better-preserved cardiac function, although metabolic activity measured by PET did not differ significantly between groups. Moreover, early CMR and PET measurements proved to be strong predictors of long-term outcomes.

These findings underscore the value of combined PET/CMR imaging for monitoring disease progression and evaluating new therapeutic strategies in preclinical cardiovascular research.

NANBIOSIS Participation

NANBIOSIS Unit 26 (NMR Biomedical Applications II) played an essential role in the project by providing both expert technical support—via technician and co-author Mustafa Ezzeddin—and access to its specialized imaging facilities.

“To continue advancing the Biomedical and Metabolomics Imaging section, we are pleased to share that we have published an article using a murine model of acute myocardial infarction, employing 3T MRI and PET-CLIP-ON techniques.”

—Mustafa Ezzeddin, technician at Unit 26 of NANBIOSIS

About NANBIOSIS Unit 26

Located at the Faculty of Medicine of the University of Valencia (UV), Unit 26 offers advanced NMR-based metabolomic and imaging capabilities, including a 14T NMR system for biofluid, cell line, and tissue metabolic profiling. The Unit is coordinated by Dr. Ramón Martínez-Máñez, Principal Investigator of the Applied Molecular Chemistry Group at the Universitat Politècnica de València and Scientific Director of NANBIOSIS, together with Dr. Salvador Gil, Director of the Central Service for Experimental Research (SCSIE).

Reference: DOI

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Glucose-Powered Nanomotors Achieve Deeper Drug Delivery in Solid Tumors

Glucose-powered nanomotors developed by UPV researchers boost drug delivery deep inside solid tumors, showing strong efficacy in advanced preclinical models.

Valencia, November 2025 — A research team from the Universitat Politècnica de València (UPV), part of the Interuniversity Institute for Molecular Recognition and Technological Development (IDM), has developed glucose-driven nanomotors capable of autonomously navigating solid tumors and delivering chemotherapy drugs more effectively. The work, validated in animal models and patient-derived samples, has been published in ACS Nano.

The study involved researchers from IIS La Fe, CIBER-BBN, CIBERONC, INCLIVA, and the Príncipe Felipe Research Center (CIPF). Prof. Ramón Martínez-Mañez, Scientific Director of NANBIOSIS, is the corresponding author.

Nanomotors That Use Tumor Glucose as Fuel

Poor penetration of chemotherapeutic agents into the inner tumor layers remains a major challenge in cancer treatment. As explained by the corresponding author, Ramón Martínez-Máñez — Director of IDM at UPV, CIBER-BBN researcher, and Coordinator of NANBIOSIS Unit 26 — the new Janus nanomotors help overcome this barrier by using glucose in the tumor microenvironment as a natural fuel source.

These nanomotors combine mesoporous silica nanoparticles loaded with doxorubicin and catalytic platinum nanodendrites. Their motion is powered by glucose oxidase (GOx), which converts glucose into hydrogen peroxide. Platinum then decomposes this peroxide into oxygen, enabling propulsion and enhancing drug penetration into tumor tissue.

A Multifunctional Approach to Improve Cancer Therapy

According to Paula Díez (IIS La Fe), the nanomotors not only move through the tumor but also reduce available glucose, depriving cancer cells of energy. The reaction generates oxygen, which helps reduce tumor hypoxia, and reactive oxygen species that amplify the therapeutic effect.

Alba García-Fernández (CIBER-BBN) highlights that the Janus structure enables the nanomotors to travel deeper into tumors and release the drug on demand, triggered by intracellular proteases. This design improves both targeting and delivery efficiency.

Proven Efficacy in Advanced Preclinical Models

The nanomotors showed a strong anticancer effect in cell cultures, tumor spheroids, patient-derived organoids, and a mouse model of solid tumors. In vivo, the treatment significantly reduced tumor size and increased drug concentration in the tumor core.

“These results in patient-derived breast cancer organoids demonstrate the potential of this technology for personalized cancer therapies,” note Iris Garrido and Juan Miguel Cejalvo (INCLIVA).

About NANBIOSIS Unit 26

NANBIOSIS Unit 26, located at the Faculty of Medicine of the University of Valencia and coordinated by Prof. Martínez-Máñez, offers high-field NMR infrastructure (14T) for metabolic profiling of biofluids, tissues, and cell lines. While the Unit did not directly participate in this study, its coordinator leads the research team behind this breakthrough in nanomedicine.

Reference

Andrea Escudero, Francisco J. Hicke, Elena Lucena-Sánchez, Sandra Pradana-López, Juan José Esteve-Moreno, Víctor Sanz-Álvarez, Iris Garrido-Cano, Sandra Torres-Ruiz, Juan Miguel Cejalvo, Alba García-Fernández, Paula Díez, and Ramón Martínez-Máñez. ACS Nano 2025 19 (22), 20932-20955. DOI: 10.1021/acsnano.5c03799

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

NANBIOSIS U25 Showcases Innovative MRI Research at the 41st ESMRMB Annual Scientific Meeting in Marseille

NANBIOSIS U25 presented innovative MRI research on CAM cancer models at the ESMRMB 2025 meeting in Marseille, highlighting advances in preclinical imaging.

Marseille, October 2025 — Unit 25 of NANBIOSIS – the Biomedical Applications of Nuclear Magnetic Resonance platform at the Universitat Autònoma de Barcelona (UAB) – participated in the 41st Annual Scientific Meeting of the European Society for Magnetic Resonance in Biology and Medicine (ESMRMB), held in Marseille from 9–11 October. The event gathered leading experts in magnetic resonance imaging (MRI), spectroscopy, and biomedical imaging to discuss advances shaping the future of the field.

Unit 25 presented new research on longitudinal MRI in emerging preclinical cancer models, reinforcing its longstanding expertise in advanced NMR-based biomedical applications.

Presentation of Cutting-Edge Research on Novel Preclinical Models

The work, presented on site by Dr. Ana Paula Candiota, Scientific Director of Unit 25, was carried out in collaboration with Dr. Silvia Lope-Piedrafita, Scientific Coordinator of the Unit, and the Josep Carreras Leukemia Research Institute.

The study, accepted as a late abstract, is entitled: “Longitudinal MRI for tumor evaluation in two immunocompetent chicken chorioallantoic membrane (CAM) cancer xenograft models: A Registered Report.”

The research highlights the potential of the CAM model as a novel immunocompetent platform for cancer studies. Despite inherent challenges—such as model size and magnetic susceptibility effects—the preliminary MRI results show strong promise. The study demonstrates that longitudinal MR approaches can effectively monitor tumour progression in CAM xenografts, opening the door to alternative, cost-effective, and ethically favourable preclinical cancer models.

About NANBIOSIS Unit 25: Biomedical Applications of Nuclear Magnetic Resonance

Unit 25 is inegrated within the Servei de Ressonància Magnètica Nuclear (SeRMN), which provides Nuclear Magnetic Resonance instrumentation and technical support. The Unit, lead by Dr. Ana Paula Candiota, has a recognized record of excellence in applying NMR to biomedical research. This service provides access to state-of-the-art equipment and capabilities, such as 10 spectrometers operating between 5.8 and 14.1 Tesla, including a 7T Bruker BioSpec MRI scanner dedicated to preclinical research.

A unique integrated environment

Unit 25 offers unparalleled access to in vivo, ex vivo, and in vitro NMR systems in a single location, along with molecular imaging tools using polarization.

This configuration enables the validation of in vivo molecular imaging results through complementary in vitro analyses, significantly strengthening translational research outcomes.

Strengthening NANBIOSIS Visibility in the European MRI Community

The presence of Unit 25 at ESMRMB 2025 underscores NANBIOSIS’ commitment to supporting cutting-edge biomedical imaging research and fostering high-impact collaborations internationally. The presentation in Marseille further consolidated the Unit’s visibility within the European MRI community and highlighted the relevance of novel preclinical models in advancing cancer research.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

NANBIOSIS Unit 6 highlights cutting-edge biointeraction techniques at BIOMED 2025 Workshop

NANBIOSIS U6 contributed to BIOMED 2025 at ICMAB with a talk on ITC and SPR, showcasing advanced tools for biomolecular interaction analysis.

Barcelona, October 2025 — last 22 October 2025, the Institute of Materials Science of Barcelona (ICMAB–CSIC) hosted the BIOMED 2025: Workshop on Experimental Techniques for Biomedicine, bringing together early-career researchers to explore pivotal biomedical characterization methods.

As a key contributor, NANBIOSIS Unit 6, the Soft Materials Service at ICMAB-CSIC, showcased its expertise through a technical talk delivered by David Piña Muñoz — “Unraveling and Quantifying Molecular Biointeractions through ITC and SPR.” This presentation underscored the Unit’s advanced instrumentation capabilities in isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR).

Unpacking ITC and SPR capabilities

During his talk, David Piña explained how ITC provides thermodynamic profiles of molecular interactions by directly measuring heat changes upon binding, offering insights into binding affinity, stoichiometry, enthalpy, and entropy. Meanwhile, SPR enables real-time, label-free monitoring of biomolecular binding kinetics — capturing association and dissociation rates with high sensitivity. Together, these complementary techniques empower researchers to comprehensively characterize biomolecular interactions.

These services are part of the broader Soft Materials platform at Unit 6, which integrates a suite of advanced characterization tools tailored for soft and biomaterials research.

About NANBIOSIS Unit 6: Soft Materials Service

NANBIOSIS Unit 6 is based at ICMAB–CSIC in Barcelona, coordinated by Prof. Nora Ventosa, who also leads the NANOMOL group. The Unit specializes in the development, processing, and characterization of nano- and microstructured molecular soft materials with therapeutic or biomedical relevance.

A standout capability of Unit 6 is its compressed-fluid biomaterials processing platform, including the proprietary DELOS-SUSP one-step method using compressed CO₂. This technology enables the scalable production of particulate biomaterials with controlled size, internal structure, and supramolecular organization — from milliliters to liters. The Unit is also ISO 9001 certified, ensuring high-quality standards across its operations.

Impact of the BIOMED 2025 Workshop

The BIOMED 2025 workshop was designed to support early-stage biomedical researchers, offering a hybrid format (in-person and online) that covered a spectrum of techniques — from cell culture basics to advanced biophysical analysis. By delivering a session on ITC and SPR, NANBIOSIS Unit 6 not only contributed scientific knowledge but also reinforced its role as a core technology provider for the biomedical community.

Participants benefited from expert-led discussions, hands-on insights into characterization tools, and networking opportunities with leading researchers in materials science and biomedicine.

Further Information & Contacts

• Soft Materials Service, ICMAB-CSIC: Visit the SOFT ICMAB website for more details on instrumentation and services.
• NANBIOSIS Unit 6: Learn about U6 – Soft Materials Service, its research lines, and technological capabilities.
• Contact: You can reach the SOFT Materials Service at ICMAB via servicios.soft@icmab.es.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Young researchers from CIBERES and CIBER-BBN connect in El Escorial to advance biomedical research and micro-nano technologies

Young researchers from CIBERES and CIBER-BBN met in El Escorial, where NANBIOSIS presented its organ-on-chip project “Chips R Us”.

Madrid, November 2025 — More than sixty young researchers from the CIBERES and CIBER-BBN networks gathered at the Euroforum center for the 2025 CIBERES–CIBER-BBN Young Researchers Conference (Jornadas de Personal Investigador Joven). The event fostered collaboration between early-career scientists in biomedical engineering, nanomedicine, and respiratory research, while highlighting the role of advanced micro- and nanotechnologies in healthcare innovation.

A platform for collaboration and emerging research

Organized by CIBERES (CIBER area of Respiratory Diseases) in collaboration with CIBER-BBN (CIBER area of Bioengineering, Biomaterials, and Nanomedicine), the two-day conference promoted knowledge exchange and interdisciplinary cooperation.

The program included talks on international funding opportunities, citizen engagement in biomedical research, and multiple sessions dedicated to oral and poster communications covering fields such as nanoparticles for targeted therapy, respiratory infection diagnostics, sleep apnea detection, and biomimetic organ-on-chip models.

NANBIOSIS presents “Chips R Us”: advancing organ-on-chip technology

A highlight of the event was the presentation of “Chips R Us”, a project coordinated by NANBIOSIS, Spain’s distributed research infrastructure for biomaterials and nanomedicine. The project was introduced by Gabriel Alfranca, Communication Manager of NANBIOSIS and coordinator of the project, alongside Denise Marrero (CIBER-BBN), a researcher in the group led by Dr. Rosa Villa and Dr. Xavier Illa at the Microelectronic Institute of Barcelona (IMB-CNM, CSIC), where NANBIOSIS Unit 8 – Micro-Nano Technologies is located.

Their presentation showcased the project’s goal of developing organ-on-chip platforms — particularly lung-on-chip models — to improve disease diagnostics and enable tailored therapeutic strategies. These innovative microdevices are fabricated using the clean-room facilities of IMB-CNM, Spain’s largest installation for micro- and nanofabrication processes.

NANBIOSIS Unit 8: a cornerstone for biomedical microfabrication

NANBIOSIS Unit 8 is very close collaboration with the MICRONANOFABS network, a Singular Scientific and Technical Infrastructure (ICTS), same category as NANBIOSIS. The Unit offers expertise in CVD graphene fabrication, photolithography, metallization, and flexible biocompatible substrates such as polyimide and parylene — key technologies for creating biomedical implants, neuroprostheses, and organ-on-chip devices.

By integrating microelectronics and biotechnology, Unit 8 enables researchers from both academia and industry to translate nanotechnology into functional biomedical solutions. The Unit’s support for Chips R Us exemplifies how NANBIOSIS infrastructures accelerate innovation across disciplines.

Empowering young scientists in translational research

Throughout the sessions, early-career scientists from CIBERES and CIBER-BBN demonstrated their expertise in cutting-edge topics such as molecular biosensing, nanodiagnostics, respiratory disease modeling, and advanced biomaterials. The conference also featured networking sessions like “Posters & Beers,” where participants exchanged ideas in an informal setting.

In closing remarks, the organizers emphasized the importance of interdisciplinary collaboration and the role of national research infrastructures like NANBIOSIS in supporting translational and applied research. Events such as these not only strengthen cooperation among research centers but also provide young investigators with the tools and connections to shape the future of biomedical innovation.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

NANBIOSIS Showcases Biosensor Innovation as Sponsor of EBS2025 in Tarragona

NANBIOSIS sponsored EBS2025 in Tarragona, showcasing the advances of Units 2 & 29 in antibodies and oligonucleotides for next-gen biosensors.

Tarragona, October 2025 — NANBIOSIS proudly participated as an official sponsor of the 5th European Biosensor Symposium (EBS2025), held from 26 to 29 October 2025 in Tarragona. The international event, chaired by Prof. Dr. M. Pilar Marco (IQAC-CSIC / CIBER-BBN and Scientific Director of Unit 2 of NANBIOSIS), brought together hundreds of researchers, engineers and industry leaders to discuss the latest advances in biosensors, nanotechnology, microfluidics, and diagnostic devices.

Through its Unit 2 and Unit 29, NANBIOSIS highlighted its key role in supporting cutting-edge biosensor research and development — from custom antibody generation to oligonucleotide synthesis — providing essential technological capabilities for the next generation of diagnostic and monitoring tools.

NANBIOSIS: Driving Innovation in Biosensor Research

As a national Singular Scientific and Technical Infrastructure (ICTS), NANBIOSIS provides open access to advanced facilities and expert support in biomedicine, nanomedicine, biomaterials and biosensors.
Its participation in EBS2025 reinforces the infrastructure’s mission to bridge academic research and industrial innovation, helping translate discoveries into practical applications that benefit health, environment, and society.

Unit 2: Custom Antibody Service (CAbS-Nb4D-CSIC)

Represented at the symposium by members of the Nanobiotechnology for Diagnostics (Nb4D) group at IQAC-CSIC, Unit 2 showcased its extensive experience in the design, production and characterization of custom immunoreagents.

The Custom Antibody Service (CAbS) provides comprehensive solutions for hapten synthesis, monoclonal and polyclonal antibody generation, and antibody conjugation with enzymes, fluorophores or nanoparticles.
Its ISO 9001:2015-certified processes ensure high-quality reagents for biosensing applications across sectors such as medical diagnostics, food safety, environmental monitoring, and biomarker detection.

During EBS2025, the Nb4D group, which also chaired the conference, presented advances in immunosensor design and analytical performance optimization, highlighting how antibody engineering can enhance biosensor sensitivity and selectivity.

Unit 29: Oligonucleotide Synthesis Platform (OSP)

Also based at IQAC-CSIC, Unit 29 – the Oligonucleotide Synthesis Platform (OSP) – plays a pivotal role in developing nucleic-acid-based biosensors. The unit specializes in the synthesis, purification and characterization of modified oligonucleotides, including DNA and RNA derivatives conjugated with lipids, peptides or carbohydrates.

At EBS2025, Unit 29 representatives engaged with researchers developing aptamer-based biosensors and nucleic acid diagnostics, exploring opportunities for collaboration in sequence modification, bioconjugation and sensor surface functionalization.

These capabilities align closely with current trends in biosensing and nanotechnology, where hybrid bio-nano systems are key to creating more sensitive, specific, and portable diagnostic devices.

Strengthening Collaboration in the European Biosensor Community

EBS2025 offered NANBIOSIS a valuable opportunity to connect with international experts, startups, and industry partners. The symposium’s scientific sessions showcased breakthroughs in AI-enhanced biosensors, organ-on-chip models, nanomaterial-based detection, and wearable diagnostic technologies.

Through its sponsorship and active participation, NANBIOSIS reaffirmed its role as a strategic partner in European biosensor research, offering comprehensive services that cover the entire innovation pipeline – from biomolecule design to device functionalization and validation.

About the European Biosensor Symposium 2025

The 5th European Biosensor Symposium (EBS2025) took place in the Tarragona Exhibition and Congress Center, gathering leading scientists from academia and industry. The event was organized by IQAC-CSIC and CIBER-BBN, under the leadership of Prof. M. Pilar Marco, with support from sponsors such as NANBIOSIS, Universitat Rovira i Virgili (URV), and Reial Acadèmia de Farmàcia de Catalunya.

The symposium addressed emerging trends in biosensing technologies, micro- and nanofabrication, artificial intelligence for diagnostics, and organ-on-chip platforms – reflecting the multidisciplinary nature of modern biosensor research.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them: